Drug updated on 4/16/2024
| Dosage Form | Injection (subcutaneous; 16.6 mg/0.416 mL, 23 mg/0.574 mL, 32.4 mg/0.81 mL in single-dose prefilled syringes) |
| Drug Class | Complement inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive.
Summary
- Zilucoplan (Zilbrysq) is utilized for the management of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive. It demonstrates effectiveness in reducing the quantitative myasthenia gravis score (QMGS), showcasing its role in enhancing clinical results for patients with gMG.
- The information stems from three systematic reviews/meta-analyses, highlighting Zilucoplan alongside other novel therapies in the context of generalized myasthenia gravis treatment.
- In a comparison of efficacy and ranking, Zilucoplan is positioned third after batoclimab and eculizumab based on its capacity to decrease QMGS. Conversely, drugs like nipocalimab have shown lower efficacy.
- In assessing the safety profile, Zilucoplan displayed no significant difference from placebo regarding adverse events. However, it is associated with a lower incidence of adverse events compared to some treatments, with batoclimab leading in safety among the assessed options.
- Subgroup considerations and population types indicate a variable response to therapy, which could guide personalized treatment strategies based on individual patient factors, for example, prior thymectomy.
- The documents collectively underscore the necessity for more thorough studies to examine the long-term effects and safety profiles, including that of Zilucoplan, due to wide credible intervals (CrIs) and variability noted among different studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zilbrysq (zilucoplan) Prescribing Information. | 2023 | UCB, Inc., Smyrna, GA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The efficacy and safety of different targeted drugs for the treatment of generalized Myasthenia Gravis: a systematic review and Bayesian network meta-analysis. | 2024 | CNS Drugs |
| Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. | 2023 | European Journal of Neurology |
| Quantitative evaluation of drug efficacy in the treatment of Myasthenia Gravis. | 2021 | Expert Opinion on Investigational Drugs |